SCHEMBL7068622

SCHEMBL7068622

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(CN4CC5CC4CC5=O)nc3)c3ccccc23)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.60
ABL1 P00519 2/20 0.60
RAF1 P04049 2/20 0.60
LYN P07948 2/20 0.60
MAPK9 P45984 2/20 0.60
MAPK14 Q16539 10/20 0.52
TNF P01375 6/20 0.52
MAPK12 P53778 7/20 0.44
MAPK13 O15264 2/20 0.44
MAPK11 Q15759 2/20 0.44
DDR2 Q16832 2/20 0.44
HCK P08631 4/20 0.43
BRAF P15056 2/20 0.43
CIT O14578 1/20 0.43
MUSK O15146 1/20 0.43
MAP3K7 O43318 1/20 0.43
RIPK2 O43353 1/20 0.43
STK10 O94804 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081728 0.87 ABL1 (0.62) SRCABL1RAF1LYNMAPK9
SCHEMBL4087772 0.83 ABL1 (0.70) SRCABL1RAF1LYNMAPK9
SCHEMBL13527345 0.83 ABL1 (0.76) SRCABL1RAF1LYNMAPK9
SCHEMBL7687888 0.82 SRC (0.65) SRCABL1RAF1LYNMAPK9
SCHEMBL4091524 0.82 ABL1 (0.88) SRCABL1RAF1LYNMAPK9
SCHEMBL4087857 0.81 ABL1 (0.72) SRCABL1RAF1LYNMAPK9
SCHEMBL4096212 0.81 SRC (0.64) SRCABL1RAF1LYNMAPK9
SCHEMBL4081491 0.81 ABL1 (0.69) SRCABL1RAF1LYNMAPK9
SCHEMBL4087232 0.80 SRC (0.62) SRCABL1RAF1LYNMAPK9
SCHEMBL4085862 0.79 MAPK14 (0.61) SRCABL1RAF1LYNMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220336-A1 Method of treating mucus hypersecretion BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-11-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220336-A1 Method of treating mucus hypersecretion MUC1, CFTR, MAPKAPK5 SRC 1828/4885ABL1 719/4885RAF1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.